- Home
- GOVX vs JFU Comparison
GOVX vs JFU Comparison
Compare GOVX & JFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- JFU
- Stock Information
- Founded
- GOVX 2001
- JFU 2006
- Country
- GOVX United States
- JFU China
- Employees
- GOVX N/A
- JFU N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- JFU Finance: Consumer Services
- Sector
- GOVX Health Care
- JFU Finance
- Exchange
- GOVX Nasdaq
- JFU Nasdaq
- Market Cap
- GOVX 16.8M
- JFU 17.1M
- IPO Year
- GOVX N/A
- JFU 2019
- Fundamental
- Price
- GOVX $0.51
- JFU $4.54
- Analyst Decision
- GOVX Strong Buy
- JFU
- Analyst Count
- GOVX 3
- JFU 0
- Target Price
- GOVX $10.67
- JFU N/A
- AVG Volume (30 Days)
- GOVX 742.0K
- JFU 51.1K
- Earning Date
- GOVX 11-07-2025
- JFU 01-01-0001
- Dividend Yield
- GOVX N/A
- JFU N/A
- EPS Growth
- GOVX N/A
- JFU 3110.57
- EPS
- GOVX N/A
- JFU 3.04
- Revenue
- GOVX $6,143,044.00
- JFU $44,573,690.00
- Revenue This Year
- GOVX N/A
- JFU N/A
- Revenue Next Year
- GOVX N/A
- JFU N/A
- P/E Ratio
- GOVX N/A
- JFU $1.63
- Revenue Growth
- GOVX 1943.07
- JFU 8.19
- 52 Week Low
- GOVX $0.43
- JFU $1.01
- 52 Week High
- GOVX $3.88
- JFU $5.88
- Technical
- Relative Strength Index (RSI)
- GOVX 39.70
- JFU 53.96
- Support Level
- GOVX $0.54
- JFU $4.40
- Resistance Level
- GOVX $0.61
- JFU $5.00
- Average True Range (ATR)
- GOVX 0.03
- JFU 0.33
- MACD
- GOVX -0.00
- JFU -0.12
- Stochastic Oscillator
- GOVX 14.50
- JFU 9.72
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.